The estimated Net Worth of Coelho Rogerio Vivaldi is at least $3.07 Milhão dollars as of 21 July 2023. Dr Vivaldi owns over 5,528 units of Sigilon Therapeutics stock worth over $268,809 and over the last 10 years he sold SGTX stock worth over $2,002,850. In addition, he makes $802,372 as Pres e CEO & Director at Sigilon Therapeutics.
Dr has made over 10 trades of the Sigilon Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 5,528 units of SGTX stock worth $106,359 on 21 July 2023.
The largest trade he's ever made was buying 41,667 units of Sigilon Therapeutics stock on 30 June 2014 worth over $250,002. On average, Dr trades about 6,198 units every 127 days since 2014. As of 21 July 2023 he still owns at least 11,963 units of Sigilon Therapeutics stock.
You can see the complete history of Dr Vivaldi stock trades at the bottom of the page.
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA is the Pres, CEO & Director at Sigilon Therapeutics.
As the Pres e CEO & Director of Sigilon Therapeutics, the total compensation of Dr MBA at Sigilon Therapeutics is $802,372. There are no executives at Sigilon Therapeutics getting paid more.
Dr MBA is 57, he's been the Pres e CEO & Director of Sigilon Therapeutics since . There are 1 older and 4 younger executives at Sigilon Therapeutics. The oldest executive at Sigilon Therapeutics, Inc. is Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD, 72, who is the Co-Founder & Member of Scientific Advisory Board.
Coelho's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui..., eJohn Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon Therapeutics executives and other stock owners filed with the SEC include: